Context Therapeutics (6K9) Stock Overview
A biopharmaceutical company, develops products for the treatment of solid tumors. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
6K9 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Context Therapeutics Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.41 |
| 52 Week High | US$1.41 |
| 52 Week Low | US$0.44 |
| Beta | 1.91 |
| 1 Month Change | 67.86% |
| 3 Month Change | 39.60% |
| 1 Year Change | 20.51% |
| 3 Year Change | 19.23% |
| 5 Year Change | n/a |
| Change since IPO | -74.85% |
Recent News & Updates
Recent updates
Shareholder Returns
| 6K9 | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 53.3% | 2.5% | 1.8% |
| 1Y | 20.5% | 11.1% | 14.5% |
Return vs Industry: 6K9 exceeded the German Pharmaceuticals industry which returned 9.8% over the past year.
Return vs Market: 6K9 exceeded the German Market which returned 13.6% over the past year.
Price Volatility
| 6K9 volatility | |
|---|---|
| 6K9 Average Weekly Movement | 15.6% |
| Pharmaceuticals Industry Average Movement | 6.2% |
| Market Average Movement | 5.1% |
| 10% most volatile stocks in DE Market | 12.2% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: 6K9's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 6K9's weekly volatility (16%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 12 | Martin Lehr | www.contexttherapeutics.com |
Context Therapeutics Inc., a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy.
Context Therapeutics Inc. Fundamentals Summary
| 6K9 fundamental statistics | |
|---|---|
| Market cap | €121.45m |
| Earnings (TTM) | -€22.55m |
| Revenue (TTM) | n/a |
Is 6K9 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 6K9 income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$26.44m |
| Earnings | -US$26.44m |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.29 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did 6K9 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/01/05 09:56 |
| End of Day Share Price | 2026/01/05 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Context Therapeutics Inc. is covered by 11 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Li Wang Watsek | Cantor Fitzgerald & Co. |
| Silvan Tuerkcan | Citizens JMP Securities, LLC |
| Jason Kolbert | D. Boral Capital LLC. |